A821 addition, CRT was projected to be cost-effective, with incremental cost-effectiveness ratios ranging from MXN 375,458 (vs. CRZ) to MXN 610,125 (vs. PC). Deterministic and probabilistic sensitivity analyses demonstrated that results were robust across model inputs and assumptions. ConClusions: CRT was projected to result in the best health outcomes for PT/CN-EX ALK+ NSCLC patients compared to current treatment regimens in Mexico, while also being a cost-effective therapy.

A929 terms: aedes aegypt AND costs, dengue AND costs, chikungunya AND costs, zika AND costs e yellow fever AND costs) and completed with hand search on the reference list of included articles. Language was limited for English or Portuguese, and publication date for 2010-2017. We extracted data on government expenditures for the treatment of patients during the outbreaks of dengue, zika, chikungunya and yellow fever in those years. In the absence of data from Brazil, the search was expanded to Latin America. Official data from the Brazilian Ministry of Health (MoH) and the World Health Organization (WHO) were also reviewed. Results: we retrieved 423 articles, 410 were excluded due to duplicity, because they did not address our topic or Latin America and due to design inadequacies. Thirteen studies were included for analysis. Data from the literature estimated the cost of treating dengue at around R$ 1 billion per year. Treatment of microcephaly and Guillain-Barre syndrome, the most severe consequences of zika, was estimated at U$91,102. The economic impact of chikungunya treatment was projected at U$73.6 million. For the current outbreak of yellow fever, the economic impact has not yet been estimated. The Brazilian government has spent R$ 13.7 million to combat aedes aegypt according to official data from MoH since the outbreak of dengue in 2013. ConClusions: There is a need for greater investment in the prevention and control of the vector, which would save resources and avoid new outbreaks of these and other diseases transmitted by aedes aegypt.

period evaluated, admissions of elderly (older than 60 years) were the most frequent, accounting for 74% of the total. In addition, men were the majority, with 2.38 times more admissions for men than women. There were 4,311 deaths for the period. The total admissions cost was 120,108,156 BRL. There has also been an annual growth trend in total costs with hospital admissions. Mean cost per admission was 1,990 BRL over the four year period. ConClusions: These results suggest an increasing impact of urothelial carcinoma on SUS admissions costs, especially affecting older men. This pathology has high morbidity and mortality rates if not treated optimally, and investigational immunotherapies that train the immune system to recognize cancer cells may improve outcomes for these patients.

No abstract

S23$253,656), respectively. LOS and charges did not significantly vary by gender or race. ConCluSionS: Patients with AML incur high costs for public and private payers, mainly due to long length of stay. New treatments with shorter LOS could potentially lower the economic burden by offsetting high cost of hospitalization.